Effect of ursodeoxycholic acid on autoimmune-associated chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 14, Issue 5, 1999, Pages 413-418

  Nakamura, Kimihide ^a   Yoneda, Masashi ^a   Takamoto, Shujiro ^a   Nakade, Yukiomi ^a   Yokohama, Shiro ^a   Tamori, Keisuke ^a   Aso, Kazunobu ^a   Matui, Tomoko ^a   Sato, Yoichi ^a   Aoshima, Masaru ^a   Makino, Isao ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Autoimmunity; Bile acid; Chronic hepatitis C; Immunosuppressive agent; Ursodeoxycholic acid

Indexed keywords

INTERFERON; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNITY; BILE ACID METABOLISM; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL;

EID: 0032986776     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1999.01898.x     Document Type: Article

References (40)

1. 1 McFarlane IG. Autoimmunity and hepatotropic viruses. Semin. Liver Dis. 1991; 11: 221-33.
2. 2 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108: 157-64.
3. 3 Pawlotsky JM, Deforges L, Bretagen S et al. Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis. Gut 1993; (Suppl.): S66-8.
4. 4 Pawlotsky JM, Ben Yahia M, Andre C et al. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994; 19: 841-8.
5. 5 Clifford BD, Donahue D, Smith L et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-19.
6. 6 Dickson RC, Gaffey MJ, Ishitani MB, Roarty TP, Driscoll CJ, Caldwell SH. The international autoimmune hepatitis score in chronic hepatitis C. J. Viral Hep. 1907; 4: 121-8.
7. 7 Shindo M, Di Bisceglie AM, Hoofnagel JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1922; 102: 1406-8.
8. 8 Lisker-Melman H, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 2155-60.
9. 9 Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig. Dis. Sci. 1995; 40: 1842-4.
10. 10 Garcia-Buey L, Garcia-Monzon C, Rodriguez S et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-7.
11. 11 Fong TL, Valinluck B, Govindarajan S, Charboeau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196-9.
12. 12 Magrin S, Craxi A, Fabiano C at al. Hepatitis C viremia in chronic liver disease: Relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273-9.
13. 13 Chayama K, Tsubota K, Kobayashi M et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology 1996; 23: 953-7.
14. 14 Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N. Engl. J. Med. 1994; 330: 1342-7.
15. 15 Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
16. 16 Heathcote EJ, Cauch DK, Walker V et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
17. 17 Hillaire S, Boucher E, Calmus Y et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994; 107: 781-8.
18. 18 Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 1992; 16: 719-23.
19. 19 Yoshikawa M, Tsujii T, Matsumura K et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-64.
20. 20 Tanaka H, Makino Y, Miura T et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J. Immunol. 1996; 156: 1604-8.
21. 21 Nakamura K, Akiyama K, Makino I. Effect of long-term ursodeoxycholic acid treatment on serum liver enzymes and serum bile acid metabolism in chronic hepatitis. Jpn. J. Gastroenterol. 1995; 92: 62-71.
22. 22 Nakamura K, Yoneda M, Yokohama S et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 1998; 13: 490-5.
23. 23 Desmet VJ, Gerber M, Hoofnagele JH et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
24. 24 Terasaki P, Bernoco D, Park M, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. Am. J. Clin. Pathol. 1978; 69: 103-20.
25. 25 Johnson PJ, McFarlane IG, Alvarez F et al. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
26. 26 Takano S, Ito Y, Yokosuka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
27. 27 Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effect of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur. J. Gastroenterol. Hepatol. 1995; 7: 151-4.
28. 28 Kiso S, Kawata S, Imai Y et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis with high serum γ-glutamyltranspeptidase levels. J. Gastroenterol. 1996; 31: 75-80.
29. 29 Janowitz P, Kratzer W, Wechsler JG. Positive effect of ursodeoxycholic acid therapy on liver enzymes in chronic active autoimmune hepatitis: A pilot study. Leber Magen Darm 1996; 26: 310-13.
30. 30 Toda G, Zeniya M, Watanabe F et al. Present status of autoimmune hepatitis in Japan: Correlating the characteristics with international criteria in an area with a high rate of HCV infection. J. Hepatol. 1997; 26: 1207-12.
31. 31 Cassani F, Cataleta M, Valentini P et al. Serum autoantibodies in chronic hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-6.
32. 32 Zeniya M, Aizawa Y, Watanabe F et al. HCV-marker-positive autoimmune-type chronic active hepatitis: A possible relation between HCV infection and liver auto-reaction. Liver 1994; 14: 206-12.
33. 33 Van Thiel DH, Molloy PJ, Friedlander L et al. Interferon a treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. Hepatogastroenterology 1995; 42: 900-6.
34. 34 Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartin P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J. Hepatol. 1996; 24: 308-12.
35. 35 Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: Favorable response to prednisone and azathioprine. Ann. Intern. Med. 1995; 123: 32-4.
36. 36 Tran A, Benzaken S, Yang G et al. Chronic hepatitis C and autoimmunity. Good response to immunosuppressive treatment. Dig. Dis. Sci. 1997; 42: 778-80.
37. 37 Lu CL, Chan CY, Hwang SJ, Lu RH, Lee SD. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 1995; 10: 432-7.
38. 38 Tubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
39. 39 Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
40. 40 Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113: 558-66.